Cardiotoxicity of Chemotherapy: A Multi-OMIC Perspective

Area of Science:

• Cardio-oncology
• Cardiovascular complications
• Cancer treatment side effects

Background:

• Chemotherapy-induced cardiotoxicity is a major concern in cancer care, causing significant cardiovascular complications in 10% of patients.
• Lung cancer patients are particularly susceptible to arrhythmias, cardiac failure, and other cardiac issues due to cancer treatments.
• Cardiotoxic effects damage cardiomyocytes, leading to impaired contractility and fibrosis, with risks escalating with repeated treatments.

Purpose of the Study:

• To explore the xenobiotic nature of chemotherapy agents and their detrimental effects on cardiovascular health.
• To identify novel biomarkers for early detection of cardiotoxicity.
• To discover new therapeutic targets for mitigating chemotherapy-induced cardiotoxicity in cancer survivors.

Main Methods:

• Review of existing literature on chemotherapy-induced cardiotoxicity.
• Analysis of multi-omics data to understand cellular and molecular mechanisms.
• Investigation of protein modifications like ubiquitination and phosphorylation in cardiotoxicity.

Main Results:

• Chemotherapy agents can cause cardiomyocyte deformation, contractility dysfunction, and fibrosis.
• Current treatments like ACE inhibitors and beta-blockers manage symptoms but do not prevent cell death.
• Multi-omics approaches suggest targeting specific pathways and protein modifications as potential therapeutic strategies.

Conclusions:

• There is a critical need for novel therapies to prevent and manage cardiovascular defects in cancer survivors.
• Targeting specific molecular pathways and protein modifications offers promising avenues for future treatments.
• Identifying new biomarkers and therapeutic targets is essential for improving long-term outcomes for cancer patients.